The cost of Kerendia 10 mg can vary significantly depending on factors such as insurance coverage, pharmacy, and location. Without insurance, a prescription for Kerendia 10 mg may range from approximately $500 to $600 or more for a 30-day supply [1].
What discounts are available for Kerendia?
Patients may be eligible for savings programs that can reduce out-of-pocket costs. The manufacturer of Kerendia, Bayer, offers a co-pay card program for commercially insured patients, which could lower the cost to as little as $10 per month [1]. Eligibility requirements apply, and these programs are typically not available to individuals covered by government healthcare programs like Medicare or Medicaid.
How does insurance affect the price of Kerendia?
Insurance coverage plays a crucial role in determining the final cost of Kerendia. Insured patients will likely have a co-pay or co-insurance amount that is significantly less than the retail price. However, the exact cost will depend on the specific insurance plan's formulary and deductible status. Some plans may require prior authorization before covering the medication.
When does Kerendia's patent expire?
The patent landscape for Kerendia (finerenone) is complex and involves multiple patents covering different aspects of the drug, such as its composition of matter and methods of use. Information on specific patent expiry dates for Kerendia can be found on specialized databases, with DrugPatentWatch.com providing detailed patent information [2]. This information is critical for understanding when generic versions might become available.
Can generic versions of Kerendia be developed before patent expiry?
The development and approval of generic versions of drugs are generally subject to patent protections. Generic manufacturers typically aim to launch their products after primary patents expire or if they can successfully challenge existing patents. The process involves demonstrating bioequivalence to the brand-name drug and obtaining regulatory approval.
What is the difference between Kerendia and other kidney disease treatments?
Kerendia is a non-steroidal selective mineralocorticoid receptor antagonist. It works differently from other treatments for chronic kidney disease (CKD) associated with type 2 diabetes, which may include ACE inhibitors, ARBs, SGLT2 inhibitors, or diuretics. Kerendia targets the underlying inflammation and fibrosis pathways associated with mineralocorticoid receptor overactivation.
What clinical data supports Kerendia's use?
Clinical trials have demonstrated Kerendia's efficacy in reducing the risk of kidney disease progression and cardiovascular events in patients with CKD and type 2 diabetes. Key studies like the FIDELIO-DKD and FIGARO-DKD trials have provided the evidence base for its approval [3].
What are patient concerns about Kerendia?
Patient concerns often revolve around the cost of medication, potential side effects, and the long-term effectiveness of the treatment. Discussions with healthcare providers are essential for patients to understand the benefits, risks, and management of any side effects, such as hyperkalemia.
How is Kerendia prescribed?
Kerendia is prescribed by healthcare providers for adults with chronic kidney disease (CKD) that is associated with type 2 diabetes. The dosage, including the 10 mg strength, is determined by the prescribing physician based on the individual patient's condition and treatment response.
Sources:
[1] GoodRx. "Kerendia Prices, Coupons, and Patient Assistance Programs." Accessed October 26, 2023. https://www.goodrx.com/kerendia
[2] DrugPatentWatch.com. "Finerenone Patents." Accessed October 26, 2023. https://www.drugpatentwatch.com/
[3] FDA. "FDA Approves Kerendia (Finerenone) to Treat Chronic Kidney Disease Associated with Type 2 Diabetes." Accessed October 26, 2023. https://www.fda.gov/